Prostate Cancer Diagnostic Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Prostate Cancer Diagnostic Market By Test Type (Tumor Biomarker Tests, Imaging, Biopsy, Other) By Cancer Stage (Stage I, Stage II A, Stage II B, Stage III, Stage IV)By End User (Hospital Associated Labs, Independent Diagnostic Labs, Diagnostic Imaging Centers, Cancer Research Institutes,Others) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Prostate Cancer Diagnostic Market size was valued at USD 126.5 billion in 2021 and is expected to reach USD 225.4 billion by 2028, at a CAGR of 8.6% during the forecast period 2022 to 2028. Prostate cancer is the most common type of cancer in men it is characterized by the abnormal development of cells in prostate gland and it may extent in the surrounding parts of prostate gland. Prostate cancer diagnostics market is classified on the basis of product type, age, cancer stage, and geography. Prostate cancer is age dependent cancer risk of prostate cancer increases with increase in age, family history, chemical exposure, smoking, inflammation of prostate and infections are other risk factors for prostate cancer. Prostate cancer diagnostic market is expected to show significant growth over the forecast period owing to increasing prevalence of prostate cancer and technological advancements. Biopsy is expected to be dominant diagnostic tool in prostate cancer diagnosis as it is mandatory to determine the presence of cancerous lump and cause of high level of prostate-specific antigen (PSA). Imagining prostate cancer diagnostic is expected to rise in forecasted period due to technological advances in the imaging such as a newer approach to measure blood flow within the gland using a technique called color droppler ultrasound. It detects tumor more accurately. ConfirmMDx is advanced diagnosis method which is a test that looks at certain genes in the cells from a prostate biopsy sample for accurate diagnosis. Multi parametric MRI is a newer technique that can be used to help determine the extent of the cancer and how severe it might be.

Prostate Cancer Diagnostic Market

MARKET SUMMARY
-
8.6%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 8.6%
  • Largest Market– North-America
  • Fastest Growing Market– Asia-Pacific

Prostate Cancer Diagnostic Market

  • The prostate cancer diagnostic market report gives comprehensive outlook across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
  • The report on global prostate cancer diagnostic market gives historical, current, and future market sizes (US$ Mn) on the basis of test type, cancer stage, end user and region.
Key Players
  • Abbott Laboratories
  • OPKO
  • Siemens Healthcare
  • DiaSorin
  • BioMeriux
Prostate Cancer Diagnostic Market

DRIVERS AND RESTRAINTS

Increase in prostate cancer awareness, lifestyle changes and technological advances are boosting the prostate cancer diagnostic market. Diagnosis and treatment available for prostate cancer are expensive and are associated with several side effects like urinary incontinence, surgical risks like stroke, heart attack, blood clots, which may hinder the prostate cancer diagnostic market over the forecasted period.


North-America Got Significant Share

Prostate Cancer Diagnostic Market

Prostate cancer diagnostics market is classified on the basis of geography in to North America, Latin America, Europe, Asia Pacific, and Middle East and Africa. USA along with other developed countries captures major market revenues in prostate cancer diagnosis market due to growing prevalence and incidences of prostate cancer. Asia Pacific and Africa expected to offer potential to grow in forecasted period due to increase in risk factors and awareness of prostate cancer.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2016-2021) and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Prostate Cancer Diagnostic Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content


Report

Company Profile

  • Abbott Laboratories
  • OPKO
  • Siemens Healthcare
  • DiaSorin
  • BioMeriux
  • Roche
  • MDx Health
  • Beckman Coulter
  • Myriad Genetics
  • Ambry Genetics
  • Genomic Health

Description

Prostate Cancer Diagnostic Market size was valued at USD 126.5 billion in 2021 and is expected to reach USD 225.4 billion by 2028, at a CAGR of 8.6% during the forecast period 2022 to 2028. Prostate cancer is the most common type of cancer in men it is characterized by the abnormal development of cells in prostate gland and it may extent in the surrounding parts of prostate gland. Prostate cancer diagnostics market is classified on the basis of product type, age, cancer stage, and geography. Prostate cancer is age dependent cancer risk of prostate cancer increases with increase in age, family history, chemical exposure, smoking, inflammation of prostate and infections are other risk factors for prostate cancer. Prostate cancer diagnostic market is expected to show significant growth over the forecast period owing to increasing prevalence of prostate cancer and technological advancements. Biopsy is expected to be dominant diagnostic tool in prostate cancer diagnosis as it is mandatory to determine the presence of cancerous lump and cause of high level of prostate-specific antigen (PSA). Imagining prostate cancer diagnostic is expected to rise in forecasted period due to technological advances in the imaging such as a newer approach to measure blood flow within the gland using a technique called color droppler ultrasound. It detects tumor more accurately. ConfirmMDx is advanced diagnosis method which is a test that looks at certain genes in the cells from a prostate biopsy sample for accurate diagnosis. Multi parametric MRI is a newer technique that can be used to help determine the extent of the cancer and how severe it might be.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX